| 000 | 01519 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250513150126.0 | ||
| 264 | 0 | _c19981022 | |
| 008 | 199810s 0 0 eng d | ||
| 022 | _a1015-9770 | ||
| 024 | 7 |
_a10.1159/000015851 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSteiner, T | |
| 245 | 0 | 0 |
_aThe ECASS 3-hour cohort. Secondary analysis of ECASS data by time stratification. ECASS Study Group. European Cooperative Acute Stroke Study. _h[electronic resource] |
| 260 |
_bCerebrovascular diseases (Basel, Switzerland) _c |
||
| 300 |
_a198-203 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aCerebrovascular Disorders _xdrug therapy |
| 650 | 0 | 4 | _aEurope |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPlasminogen Activators _xadverse effects |
| 650 | 0 | 4 |
_aRecombinant Proteins _xadverse effects |
| 650 | 0 | 4 | _aStatistics as Topic |
| 650 | 0 | 4 |
_aThrombolytic Therapy _xadverse effects |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 |
_aTissue Plasminogen Activator _xadverse effects |
| 700 | 1 | _aBluhmki, E | |
| 700 | 1 | _aKaste, M | |
| 700 | 1 | _aToni, D | |
| 700 | 1 | _aTrouillas, P | |
| 700 | 1 | _avon Kummer, R | |
| 700 | 1 | _aHacke, W | |
| 773 | 0 |
_tCerebrovascular diseases (Basel, Switzerland) _gvol. 8 _gno. 4 _gp. 198-203 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1159/000015851 _zAvailable from publisher's website |
| 999 |
_c9649790 _d9649790 |
||